Study of the Effectiveness of The COVID-19 Vaccine

Completed

• Conditions: COVID-19
• Interventions: Diagnostic Test: COVID-19 Antibody

• Registration Number: NCT05766176
• Lead Sponsor: Universitas Sebelas Maret

Brief Summary

This descriptive study examines neutralizing antibody levels against COVID-19 in health workers before and after the 2nd booster of the COVID-19 vaccine in Surakarta, Indonesia.

Detailed Description

This research is a cross-sectional study with a descriptive-analytic design, community-based, of adults who live in Surakarta (age 18 years and over) using the Google form. The inclusion criteria were health workers receiving the third or second dose of the COVID-19 vaccine. Quantitative antibody titers are checked at Prodia's laboratory. Other variables examined were the number and date of vaccination, age, sex, comorbid diseases, body mass index, AEFI symptoms after the vaccine, and history of being infected with COVID-19. In the statistical analysis using the different and regression correlation tests, the significance level of P is less than 0.05.

Study Timeline

• Study Start: 2022-07-01
• Primary Completion: 2022-10-30
• Study Completion: 2022-11-30
• Status Verified: 2023-03
• Study First Submitted: 2023-03-09
• Study First Submitted QC: 2023-03-09
• Last Update Submitted: 2023-03-09
• Study First Posted: 2023-03-13
• Last Update Posted: 2023-03-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• Health workers who receive the second booster of COVID-19 vaccination

Exclusion Criteria

• Pregnancy

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Health worker	COVID-19 Antibody	A health worker who received a second dose of booster COVID19 vaccine

Primary Outcome Measures

Name	Time	Method
quantitative anti-sars-cov-2 titers	Change of quantitative anti-sars-cov-2 titers before the second booster of vaccination COVID-19 and one month after	The quantitative Anti-SARS-CoV-2 test is an examination to measure in vitro quantitative antibodies (including IgG) against the receptor binding domain (RBD) of the SARS-CoV-2 Spike protein (S) which aims to assess the adaptive humoral immune response to the SARS-CoV-2 Spike protein. Measurement with the ECLIA method. Ratio Scale

Trial Locations

Locations (1)

Universitas Sebelas Maret Hospital; 🇮🇩 Sukoharjo, Central Java, Indonesia